胆管がん治療薬の世界市場

胆管がん治療薬の世界市場は2030年までに9億6,200万米ドルに達する見込み

2023年に8億6,380万米ドルと推定された胆管がん治療薬の世界市場は、2023年から2030年にかけてCAGR 1.6%で成長し、2030年には9億6,200万米ドルに達すると予測されます。本レポートで分析したセグメントの1つである標的療法は、CAGR 2.0％を記録し、分析期間終了までに5億9,250万米ドルに達すると予測されます。化学療法分野の成長率は、分析期間中CAGR 0.8％と推定されます。

米国市場は2億2,710万米ドルと推定、中国はCAGR 1.3％で成長すると予測

米国の胆管がん治療薬市場は、2023年に2億2,710万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに1億5,320万米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは1.3%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ1.2%と1.3%と予測されています。欧州では、ドイツがCAGR約0.5%で成長すると予測されています。

世界の胆管がん治療薬市場- 主要動向と促進要因まとめ

胆管がんとしても知られる胆管がんは、まれではあるが胆管に発生する侵攻性のがんです。初期段階では無症状であるため、進行した段階で診断されることが多く、治療が複雑化し予後を悪化させてしまいます。胆管がんの標準的な治療法には、手術、化学療法、放射線療法があります。手術、特に切除術は治癒の最良の可能性を提供するが、疾患の発現が遅いため、実行可能な患者は少数派です。切除不能症例や転移性症例に対する化学療法としては、ゲムシタビンとシスプラチンの併用療法などが一般的であるが、これらの治療は治癒よりも生存期間の延長を主目的としています。近年、標的治療薬や免疫療法が登場し、治療の新たな道が開かれ、進行胆管がん患者に希望を与えています。

胆管がん治療薬の状況は分子生物学と遺伝学の進歩によって大きく変わり、標的療法の開発につながりました。これらの治療法は、がんの成長を促進する特定の遺伝子変異や変化を攻撃するように設計されています。例えば、FGFR2（線維芽細胞増殖因子受容体2）融合やIDH1（イソクエン酸デヒドロゲナーゼ1）変異は、胆管がん患者の一部に認められ、新規薬剤の標的となっています。FGFR阻害剤であるペミガチニブとインフィグラチニブは、いずれも臨床試験で有効性を示し、FGFR2融合患者に対する新たな治療選択肢を提供しています。同様に、IDH1阻害剤であるイボシデニブは、IDH1変異胆管がん患者に対して有効性を示しています。免疫療法、特にペムブロリズマブのようなチェックポイント阻害剤も検討されているが、胆管がんにおける奏効率は他のがんと比較して控えめです。現在進行中の臨床試験では、これらの治療法の有効性を高め、耐性メカニズムを克服するための併用療法が検討されています。

胆管がん治療薬市場の成長は、いくつかの要因によってもたらされます。胆管がんの罹患率の増加は、B型肝炎やC型肝炎などの肝疾患や感染症の増加も一因となっており、治療を必要とする患者層が拡大しています。ゲノム・プロファイリングと個別化医療における技術的進歩は、対処可能な変異の同定を容易にし、それによって標的療法の開発と採用を促進しています。さらに、製薬企業による研究開発への多額の投資が、新規治療薬の強力なパイプラインにつながっています。また、希少疾病用医薬品に対する規制当局の支援や迅速な承認プロセスも市場の成長を後押ししています。さらに、標的治療や併用療法の可能性に関するヘルスケア専門家や患者の意識の高まりも需要を押し上げています。こうした動向が進化を続ける中、胆管がん治療薬市場は、技術の進歩、がん生物学への深い理解、革新的な治療戦略への強い注目によって、大きく拡大する態勢を整えています。

調査対象企業の例（全86件）

• Bold Therapeutics
• CStone Pharmaceuticals
• Genfit SA
• J-Pharma Co., Ltd.
• Lisata Therapeutics
• Owkin, Inc.
• RedHill Biopharma Ltd.
• RenovoRx, Inc.
• Servier Laboratories
• Specialised Therapeutics Australia Pty Limited
• Taiho Pharmaceutical Co., Ltd.
• Tempest Therapeutics
• TriSalus Life Sciences
• Tyra Biosciences;

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• その他欧州
• アジア太平洋
• その他の地域

第4章 競合

Global Cholangiocarcinoma Therapeutics Market to Reach US$962.0 Million by 2030

The global market for Cholangiocarcinoma Therapeutics estimated at US$863.8 Million in the year 2023, is expected to reach US$962.0 Million by 2030, growing at a CAGR of 1.6% over the analysis period 2023-2030. Targeted Therapy, one of the segments analyzed in the report, is expected to record a 2.0% CAGR and reach US$592.5 Million by the end of the analysis period. Growth in the Chemotherapy segment is estimated at 0.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$227.1 Million While China is Forecast to Grow at 1.3% CAGR

The Cholangiocarcinoma Therapeutics market in the U.S. is estimated at US$227.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$153.2 Million by the year 2030 trailing a CAGR of 1.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 1.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 0.5% CAGR.

Global Cholangiocarcinoma Therapeutics Market - Key Trends and Drivers Summarized

Cholangiocarcinoma, also known as bile duct cancer, is a rare but aggressive form of cancer originating in the bile ducts. The disease is often diagnosed at an advanced stage due to its asymptomatic nature in the early phases, which complicates treatment and worsens prognosis. Standard treatment options for cholangiocarcinoma include surgery, chemotherapy, and radiation therapy. Surgery, particularly resection, offers the best chance for a cure, but it is only feasible in a minority of patients due to the late presentation of the disease. For unresectable or metastatic cases, chemotherapy regimens typically include combinations such as gemcitabine with cisplatin, although these treatments primarily aim to prolong survival rather than cure the disease. Recently, the advent of targeted therapies and immunotherapies has provided new avenues for treatment, giving hope to patients with advanced cholangiocarcinoma.

The landscape of cholangiocarcinoma therapeutics has been significantly transformed by advances in molecular biology and genetics, leading to the development of targeted therapies. These therapies are designed to attack specific genetic mutations or alterations that drive cancer growth. For instance, FGFR2 (fibroblast growth factor receptor 2) fusions and IDH1 (isocitrate dehydrogenase 1) mutations are found in a subset of cholangiocarcinoma patients and have become targets for novel drugs. Pemigatinib and infigratinib, both FGFR inhibitors, have shown efficacy in clinical trials, offering new treatment options for patients with FGFR2 fusions. Similarly, ivosidenib, an IDH1 inhibitor, has demonstrated benefits for patients with IDH1-mutant cholangiocarcinoma. Immunotherapy, particularly checkpoint inhibitors like pembrolizumab, is also being explored, although the response rates in cholangiocarcinoma have been modest compared to other cancers. Ongoing clinical trials are investigating combinations of these therapies to enhance their effectiveness and overcome resistance mechanisms.

The growth in the cholangiocarcinoma therapeutics market is driven by several factors. The increasing incidence of cholangiocarcinoma, partly attributed to rising rates of liver diseases and infections such as hepatitis B and C, is expanding the patient population in need of treatment. Technological advancements in genomic profiling and personalized medicine are facilitating the identification of actionable mutations, thereby driving the development and adoption of targeted therapies. Furthermore, substantial investment in research and development by pharmaceutical companies is leading to a robust pipeline of novel therapeutics. Regulatory support and expedited approval processes for orphan drugs are also propelling market growth, as these incentives encourage the development of treatments for rare diseases like cholangiocarcinoma. Additionally growing awareness among healthcare professionals and patients about the potential of targeted and combination therapies is boosting demand. As these trends continue to evolve, the cholangiocarcinoma therapeutics market is poised for significant expansion, driven by technological advancements, a deeper understanding of cancer biology, and a strong focus on innovative treatment strategies.

Select Competitors (Total 86 Featured) -

• Bold Therapeutics
• CStone Pharmaceuticals
• Genfit SA
• J-Pharma Co., Ltd.
• Lisata Therapeutics
• Owkin, Inc.
• RedHill Biopharma Ltd.
• RenovoRx, Inc.
• Servier Laboratories
• Specialised Therapeutics Australia Pty Limited
• Taiho Pharmaceutical Co., Ltd.
• Tempest Therapeutics
• TriSalus Life Sciences
• Tyra Biosciences;

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Global Economic Update
  • Cholangiocarcinoma Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Increasing Incidence of Cholangiocarcinoma Expands Addressable Market Opportunity
  • Advances in Genomic Profiling Propel Development of Targeted Therapies
  • Rising Rates of Liver Diseases and Hepatitis Infections Drive Demand for Treatments
  • Technological Innovations in Personalized Medicine Strengthen Business Case for Novel Therapies
  • Growing Awareness of Targeted and Combination Therapies Accelerates Market Adoption
  • Identification of Actionable Genetic Mutations Throws Spotlight on Precision Medicine
  • Increasing Use of FGFR and IDH1 Inhibitors Drives Market Expansion
  • Exploration of Immunotherapy Combinations Generates New Opportunities
  • Challenges in Early Diagnosis and Late-Stage Presentation Propel Need for Advanced Therapeutics
  • Integration of Biomarker Testing in Treatment Planning Enhances Efficacy
  • Rising Healthcare Expenditure Expands Reach of Therapies
  • Focus on Overcoming Resistance Mechanisms Sustains Growth in Therapeutic Development
  • Adoption of Precision Oncology Approaches Drives Development of Personalized Therapies
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cholangiocarcinoma Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Cholangiocarcinoma Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 4: World 16-Year Perspective for Cholangiocarcinoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 7: World 16-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 10: World 16-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Immunotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 13: World 16-Year Perspective for Immunotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Other Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 16: World 16-Year Perspective for Other Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 19: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 22: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 25: World 16-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • TABLE 26: USA Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 27: USA Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 28: USA 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 29: USA Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 30: USA Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 31: USA 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• CANADA
  • TABLE 32: Canada Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 33: Canada Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 34: Canada 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 35: Canada Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 36: Canada Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 37: Canada 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• JAPAN
  • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • TABLE 38: Japan Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 39: Japan Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 40: Japan 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 41: Japan Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 42: Japan Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 43: Japan 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• CHINA
  • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • TABLE 44: China Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 45: China Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 46: China 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 47: China Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 48: China Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 49: China 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• EUROPE
  • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • TABLE 50: Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
  • TABLE 51: Europe Historic Review for Cholangiocarcinoma Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 52: Europe 16-Year Perspective for Cholangiocarcinoma Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • TABLE 53: Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 54: Europe Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 55: Europe 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 56: Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 57: Europe Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 58: Europe 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• FRANCE
  • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • TABLE 59: France Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 60: France Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 61: France 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 62: France Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 63: France Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 64: France 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• GERMANY
  • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • TABLE 65: Germany Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 66: Germany Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 67: Germany 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 68: Germany Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 69: Germany Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 70: Germany 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• ITALY
  • TABLE 71: Italy Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 72: Italy Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 73: Italy 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 74: Italy Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 75: Italy Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 76: Italy 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• UNITED KINGDOM
  • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • TABLE 77: UK Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 78: UK Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 79: UK 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 80: UK Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 81: UK Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 82: UK 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• REST OF EUROPE
  • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 84: Rest of Europe Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 85: Rest of Europe 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 87: Rest of Europe Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 88: Rest of Europe 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• ASIA-PACIFIC
  • Cholangiocarcinoma Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 90: Asia-Pacific Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 91: Asia-Pacific 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 93: Asia-Pacific Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 94: Asia-Pacific 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030
• REST OF WORLD
  • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 96: Rest of World Historic Review for Cholangiocarcinoma Therapeutics by Therapy - Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 97: Rest of World 16-Year Perspective for Cholangiocarcinoma Therapeutics by Therapy - Percentage Breakdown of Value Sales for Targeted Therapy, Chemotherapy, Immunotherapy and Other Therapies for the Years 2014, 2024 & 2030
  • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
  • TABLE 99: Rest of World Historic Review for Cholangiocarcinoma Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2022 and % CAGR
  • TABLE 100: Rest of World 16-Year Perspective for Cholangiocarcinoma Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2014, 2024 & 2030

IV. COMPETITION